A study to evaluate the RenalGuard System safety & efficacy when compared with standard care in the prevention of contrast induced nephropathy in the setting of a catheterization laboratory.
- Type of Study
- Heart & Vascular - Interventional Cardiology Trials
- Short Description
The purpose of this study is to see if the RenalGuard therapy is better than standard IV fluid hydration for preventing kidney problems that can happen when patients receive contrast dye during a heart catheterization procedure.
- Principal Investigator
- Paul Huang, MD
- Eligibility Notes
Inclusion: >/= 18 years of age, scheduled for elective catheterization procedure, currently have moderate to severe kidney impairment.
Exclusion: Chronic heart failure class 3 or 4, moderate to severe anemia, recent hospitalization or treatment for worsening kidney function, sensitivity to lasix(furosemide) or contrast dye, unable to have a foley catheter placed
- Contact Name
- Stephen Lubatti
- Alternate Phone